Beautiful lines..

🚨 New Insights in Cirrhosis! 🚨 www.journal-of-hepatology.eu/article/S016... Our study reveals Non-Acute Decompensation (NAD) is a distinct clinical state, different from compensated cirrhosis & acute decompensation (AD) @rajivjalan.bsky.social @jhepatology.bsky.social @akashroyy.bsky.social

@bavenocoop.bsky.social Research Committee Baveno VIII Pre-Symposium, here we go! 👍 103 members watching online 👉 High interest in designing clinical studies on PH. #liversky

Systemic inflammation🔥(SI) is a major driver of #liver disease progression in patients with decompensated #cirrhosis. Dr. Lukas Hartl now demonstrated in #JHEPReports that #TIPS not only controls #PH-related decompensation but also effectively and sustainedly decrease #SI (#IL6 levels. 🔗 t.ly/A39-U

Please delve deeper into “social” drinking with your patients, especially in those with evidence of liver disease. More often than not, drinking that is considered socially acceptable is harmful to the liver. Sometimes a brief intervention/educational moment is enough to save a liver! #liversky

🆕Article in press❕ A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH Full text here👉https://bit.ly/4iucrzV More information here👉https://bwnews.pr/4hadNie #OpenAccess #LiverSky

Spicy! Adding lasix to the management of hepatorenal syndrome might be ok if you bump the MAP with pressors @juancarlosqvelez.bsky.social doi.org/10.1016/j.ek... #nephsky #liversky

Highlighting role of hepatology in the spectrum of HCC care In this study Impact of liver decom on clinical outcomes on atezobeva 📌OS better in CP A vs CP B 📌No differences in TTP/safety 📌Liver decomp: 28% CP A vs 51% CP B 📌41% resume after decomp #Liversky www.cghjournal.org/article/S154...

What an honor to be speaking at Hot Topics at AASLD 2024 hosted by ILBS invited by one and only Dr. Shiv Sarin :) #liversky

🚀 AI & ML are transforming liver disease care! 🔬our @akashroyy.bsky.social review explores how machine learning enhances diagnosis & outcome prediction in alcohol-related & metabolic dysfunction-associated steatotic liver diseases (MASLD). 🔍 🔗 oaepublish.com/articles/mtod.…#AIA#Liverer

🔵 ClustALL paper: This innovative clustering method addresses patient heterogeneity in acutely decompensated #cirrhosis, identifying subgroups with prognostic value to improve trials and personalized care. Read more: translational-medicine.biomedcentral.com/articles/10.... #LiverSky

www.unite.ai/googles-ai-c... #AI #artificialintelligence

Fascinating discussion on PSVD, NCPF, Idiopathic portal hypertension ongoing in @jhepatology.bsky.social @valdig.bsky.social @ebtapper.bsky.social would be worth a skytutorial